Clinical features analysis of inflammatory myofibroblastic tumors of the retroperitoneal and genitourinary system

To explore the clinical features of inflammatory myofibroblastic tumors (IMT) of the retroperitoneal and genitourinary system.

We conducted a retrospective analysis of the clinical data of 23 patients with pathologically confirmed retroperitoneal and urogenital inflammatory myofibroblastic tumours who were admitted to the First Affiliated Hospital of Xiamen University between January 2010 and December 2024.

There were 10 male patients and 13 female patients, with an average age of (42.1 ± 4.1) years. The tumors were located in the retroperitoneum in 8 cases, in the bladder in 5 cases, in the kidney in 5 cases, in the spermatic cord in 2 cases, in the testis in 1 case, in the epididymis in 1 case, and in the prostate in 1 case. All 23 patients were diagnosed with space-occupying lesions before surgery.Among the 23 cases, 19 underwent surgical treatment and 4 received conservative treatment.Seven patients received postoperative adjuvant treatment. Among them, 4 patients received non-steroidal anti-inflammatory drug treatment, 3 patients had no recurrence and are currently alive, and 1 patient had recurrence and died; 1 patient received treatment with epirubicin and cisplatin, had no recurrence and is currently alive; 1 patient was treated with ifosfamide combined with epirubicin and pirarubicin, had no recurrence and is currently alive; 1 patient was treated with azathioprine and crizotinib, had no recurrence and is currently alive. As of the last follow-up, 2 patients had died, and the rest were all alive.

IMT can originate from any part of the genitourinary system, with pain being the most common symptom. Its clinical management is similar to that of malignant tumours of the genitourinary system, and complete surgical resection is the standard treatment strategy for all genitourinary IMT.